Dr Alex Tatem — A urologist specializing in men's health (low testosterone, erectile dysfunction, male fertility) who runs a popular YouTube channel educating the public on peptides and hormone therapy.
The gist
Steven Bartlett sits down with urologist Dr Alex Tatem for a deep dive on peptides: short chains of amino acids that act as targeted 'keys' for specific receptors in the body. Tatem walks through specific compounds (BPC-157, TB-500, GHK-Cu, the GLP-1 drugs semaglutide and tirzepatide, growth-hormone secretagogues and more), what each does, and the safety trade-offs. He explains the regulatory backstory: how a 2013 gene-patent ruling and a compounding-pharmacy scandal led to peptides being banned in 2023, and how the FDA is now considering moving seven peptides back to a legal, compoundable category in July. The conversation covers the gray market, GLP-1 weight loss and muscle preservation, declining male fertility, the Enhanced Games, and ends with Tatem's emotional account of his brutal surgical training and his work placing penile implants.
Big reveals
- Tatem ties the peptide ban to the 2013 Myriad Genetics Supreme Court ruling that natural genes/compounds can't be patented, removing pharma's incentive to develop them.
- In 2023 the FDA moved 19 popular peptides from the legal 'category one' to banned 'category two' overnight.
- Says RFK Jr. has characterized the 2023 peptide ban as illegal.
- Agrees '110%' that big pharma didn't want peptides in regular people's hands because they can't patent them.
- Reports an FDA press release that in July it will consider returning seven peptides (including BPC-157) to legal status.
- Claims FDA commissioner Marty Makary has tweeted more about cracking down on compounded GLP-1s than about diabetes or heart disease combined.
- Tatem opens up that grueling surgical training left him with low testosterone and a near-breakdown after a patient lost a kidney.
- Reveals he has personally placed 1,100-1,200 penile implants, a 13-minute procedure.
Things worth remembering
- Insulin, isolated in 1921, was the first peptide used in medicine.
- In animal studies BPC-157 healed fully transected Achilles tendons in rats, and its dose is so safe researchers haven't found the level that harms even 1% of subjects.
- A patient who lost 100 lb on tirzepatide saw his sperm count increase tenfold into the normal range.
- Revenue from semaglutide and tirzepatide alone is projected over $55 billion this year, approaching the combined revenue of the top four AI/LLM companies.
- Melanotan II produces a deep tan with minimal UV exposure and also causes strong erections; its derivative PT-141 (bremelanotide) is an approved prescription drug.
- Retatrutide, a triple-receptor GLP-1 drug, has produced 20-25% total body weight loss and Tatem predicts it will be a trillion-dollar drug owned solely by Lilly.
- Total sperm counts in young men have fallen dramatically since 1973, illustrated with vials of progressively clearer water.
- The Enhanced Games (Las Vegas, May 21-24) lets athletes openly use performance-enhancing drugs, offering $250K to winners and $1M for world records.
- There are 30 million men with erectile dysfunction in the US, more than the population of Australia, and oral ED drugs fail the first time for 15% of them.
- GHK-Cu is a copper tripeptide that declines with age and, applied topically, boosts collagen and elastin to improve skin.